Cardiovascular Adverse Events (CVAE) Associated With Second Generation Bruton Tyrosine Kinase (BTK) Inhibitor (BTKi) Therapy in Patients With Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Meta-Analysis

被引：0
|
作者：
Proskuriakova, Ekaterina [1 ]
Shrestha, Dhan [1 ]
Jasaraj, Ranjit [1 ]
Mercado, Gustavo Espinoza [1 ]
Wortstman, Josh [1 ]
Kovalenko, Iulia [2 ]
Khosla, Pam [1 ]
机构：
[1] Mt Sinai Hosp, Chicago, IL USA
[2] UPMC, Harrisburg, PA USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
CLL; Bruton tyrosine kinase inhibitor; acalabrutinib; zanubrutinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CLL-428
引用
收藏
页码：S327 / S328
页数：2
相关论文
共 50 条
  • [1] Cardiovascular Adverse Events Associated With Second-generation Bruton Tyrosine Kinase Inhibitor Therapy: A Systematic Review and Meta-analysis
    Proskuriakova, Ekaterina
    Shrestha, Dhan Bahadur
    Jasaraj, Ranjit
    Reddy, Vijay Ketan
    Shtembari, Jurgen
    Raut, Anuradha
    Gaire, Suman
    Khosla, Paramjeet
    Kadariya, Dinesh
    CLINICAL THERAPEUTICS, 2024, 46 (02) : 134 - 145
  • [2] Cardiovascular adverse events associated with second generation Bruton tyrosine kinase inhibitor therapy: A systematic review and meta-analysis.
    Proskuriakova, Ekaterina
    Jasaraj, Ranjit
    Gaire, Suman
    Raut, Anuradha
    Reddy, Vijay Ketan
    Shrestha, Dhan
    Kovalenko, Iuliia
    Khosla, Paramjeet Grewal
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] ACALABRUTINIB, A SECOND-GENERATION BRUTON TYROSINE KINASE (BTK) INHIBITOR, IN PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Wierda, W.
    Jones, J.
    Furman, R.
    Stephens, D.
    Devereux, S.
    Brown, J.
    Hillmen, P.
    Hamdy, A.
    Fardis, M.
    Tawashi, M.
    Wang, M. H.
    Patel, P.
    Mittag, D.
    Krantz, F.
    Rothbaum, W.
    Izumi, R.
    O'Brien, S.
    Byrd, J.
    HAEMATOLOGICA, 2016, 101 : 151 - 151
  • [4] Acalabrutinib, a second-generation bruton tyrosine kinase (Btk) inhibitor, in previously untreated chronic lymphocytic leukemia (CLL).
    Byrd, John C.
    Jones, Jeffrey Alan
    Furman, Richard R.
    Stephens, Deborah Marie
    Devereux, Steve
    Brown, Jennifer R.
    Hillmen, Peter
    Hamdy, Ahmed M.
    Fardis, Maria
    Tawashi, Manal
    Wang, Min Hui
    Patel, Priti
    Mittag, Diana
    Krantz, Fanny
    Rothbaum, Wayne
    Izumi, Raquel
    O'Brien, Susan Mary
    Wierda, William G.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] BRUTON TYROSINE KINASE INHIBITOR (BTKI) MONOTHERAPY FOR THE TREATMENT OF 'HIGH-RISK' PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A SYSTEMATIC LITERATURE REVIEW (SLR)
    Mohseninejad, L.
    Walder, L.
    Ubi, S.
    Malyon, A.
    Yang, K.
    Olie, R.
    VALUE IN HEALTH, 2023, 26 (12) : S545 - S545
  • [6] Mutations in the Bruton Tyrosine Kinase (BTK) Gene in Patients with Chronic Lymphocytic Leukemia (CLL) Receiving BTK Inhibitors (BTKis)
    Skarbnik, Alan P.
    Danilov, Alexey V.
    Hoffmann, Marc
    Awan, Farrukh T.
    Scarpa, Frank
    Davies, Caryn
    Oakland, Todd
    Kovach, Marina
    Lilyquist, Jenna
    Munugalavadla, Veerendra
    Yong, Alan S. M.
    Shetty, Vikram
    Allan, John N.
    Woyach, Jennifer A.
    BLOOD, 2024, 144 : 4623 - 4624
  • [7] Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL)
    Thompson, Philip A.
    Burger, Jan A.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2018, 27 (01) : 31 - 42
  • [8] Efficacy and Safety of Bruton Tyrosine Kinase Inhibitor Monotherapy Compared with Combination Therapy for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Systematic Review and Meta-Analysis
    Nguyen, Thi Thuy
    Nhu, Nguyen Thanh
    Tran, Van Khoi
    Nguyen, Tran Thuc Huan
    Lin, Chiou-Feng
    CANCERS, 2023, 15 (07)
  • [9] Characterization of Bruton Tyrosine Kinase Inhibitor (BTKi)-Related Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)
    Stilgenbauer, Stephan
    Seymour, John F.
    Byrd, John C.
    Hillmen, Peter
    Ghia, Paolo
    Kater, Arnon P.
    Chanan-Khan, Asher
    Furman, Richard R.
    O'brien, Susan
    Brown, Jennifer R.
    Mato, Anthony
    Kuptsova-Clarkson, Nataliya
    Miranda, Paulo
    Wagner, Dennis
    Higgins, Kara
    Sohoni, Sophia
    Jurczak, Wojciech
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 169 - 169
  • [10] Efficacy and safety of first- versus second-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: a systematic review and meta-analysis
    Ke, Liyuan
    Li, Su
    Huang, Danxue
    Wang, Yan
    FRONTIERS IN PHARMACOLOGY, 2024, 15
12345